ImpediMed Limited (IPD.AX)
| Previous close | 0.1250 |
| Open | 0.1300 |
| Bid | 0.1200 x 53590500 |
| Ask | 0.1250 x 50748300 |
| Day's range | 0.1050 - 0.1350 |
| 52-week range | 0.0490 - 0.1500 |
| Volume | |
| Avg. volume | 1,403,465 |
| Market cap | 223.208M |
| Beta (5Y monthly) | 2.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival
ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.
- PR Newswire
ImpediMed Extends Contract for AstraZeneca for Use of the SOZO Digital Health Platform in Clinical Trial of Patients with Chronic Kidney Disease
ImpediMed Limited (ASX: IPD) today announced the details of the third contract extension related to the use of its SOZO® Digital Health Platform in a clinical trial being conducted for AstraZeneca. The Phase IIb trial uses SOZO to track patient fluid volume in a pharmaceutical study focused on patients with chronic kidney disease. The trial, involving 210 SOZO devices, has been extended from 21 months to 29 months.
- PR Newswire
ImpediMed Reaches Milestone of 500,000 Patient Tests Performed with the SOZO Digital Health Platform
ImpediMed Limited (ASX: IPD) reached a milestone of 500,000 patient tests performed with the SOZO® Digital Health Platform. With over 1,100 devices in use globally, the pace of patient testing has accelerated with 100,000 patient tests performed in just the past six months. Product improvements, new clinical evidence, and comprehensive programs, such as the Lymphedema Prevention Program, have all contributed to increased utilization of SOZO by clinicians for the benefit of patients.
